|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMATOPOIESIS
From the Bone Marrow Transplant Service, Departments of
Medicine, Massachusetts General and Brigham and Women's Hospitals, and
Harvard Skin Disease Research Center, Harvard Medical School, Boston,
MA.
Human hematopoietic progenitor cells express L-selectin and also
express PSGL-1, a ligand for all selectins. Using a shear-based adhesion assay, a hematopoietic cell L-selectin ligand (HCLL) that is
expressed on the hematopoietic cell line KG1a and on normal human
hematopoietic progenitors was previously identified. To characterize the structural biology of HCLL and to define its relationship to PSGL-1, the effects of chemical and enzymatic treatments on HCLL activity of KG1a cells and membrane preparations were analyzed. Protease digestions and chemical treatments of KG1a
cells and membranes indicated that HCLL is an integral membrane glycoprotein. Glycosidase digestions of membrane protein preparations and metabolic treatments of KG1a cells with glycosylation
processing modifiers revealed that L-selectin binding determinants on
HCLL are sialofucosylated structures presented on complex-type
N-glycans. Adhesion assays and biochemical studies showed that this
glycoprotein is also expressed on circulating blasts in native acute
leukemias. HCLL is distinguishable from PSGL-1: (1) KG1a cells sorted
for PSGL-1 expression had equivalent HCLL activity; (2) anti-PSGL-1 blocking antibodies and proteases known to eliminate L-selectin binding
to PSGL-1 had no effect on HCLL binding activity of KG1a cells;
(3) blasts from native leukemias with low expression of PSGL-1 and CD34
display high HCLL activity; and (4) despite high level expression of
PSGL-1, HCLL activity was absent on HL60 cells. These data provide
first evidence of a naturally expressed membrane L-selectin ligand
expressing binding determinant(s) on an N-linked glycoconjugate. This
novel ligand may help mediate L-selectin-dependent cell-cell
adhesive interactions within the cytoarchitecture of the bone
marrow microenvironment.
(Blood. 2000;96:2765-2774) The selectins (L-, E- and P-selectin) are a family
of membrane proteins that behave as Ca++-dependent lectins
and mediate adhesive interactions under shear with their respective
ligands. Although they are best known for mediating "rolling"
adhesive interactions between leukocytes and endothelium, which are
critical to leukocyte migration from vascular to extravascular
compartments,1 the selectins While E- and P-selectin are found on endothelial cells and
platelets (P-selectin only), L-selectin is expressed on mature leukocytes and, notably, on early hematopoietic progenitor
cells.2 Expression of L-selectin on human stem cells is
associated with higher clonogenic potential of
progenitors,7 and recovery of platelet and neutrophil
counts after clinical stem cell transplantation correlates with the
number of L-selectin+/CD34+ cells
infused.8,9 Moreover, cross-linking of L-selectin on stem
cell membranes before culture increases the clonogenic capacity of the
cells in in vitro assays,12 whereas chronic addition of
anti-L-selectin antibody suppresses colony formation.13 Collectively, these data suggest that L-selectin-mediated
receptor/ligand interactions may promote hematopoiesis, and heighten
interest in defining the nature of L-selectin ligand(s) in the marrow microenvironment.
Although several L-selectin ligands have been identified, our
understanding of the structure and function of L-selectin ligands is
incomplete. For all naturally expressed glycoprotein L-selectin ligands
described to date, the binding determinants are present on sialylated,
fucosylated lactosamines displayed on O-linked carbohydrates.14,15 On lymph node high endothelial venule
(HEV) cells, multiple L-selectin ligands have been
described,16-19 all of which are glycoproteins reactive
with the monoclonal antibody MECA 79.20 One of these
ligands is a glycoform of CD34.21 Although present on
endothelial cells in most tissues, CD34 is an integral membrane
glycoprotein best known as a marker of the multilineage colony-forming
hematopoietic "stem cell."22 This marker was originally
identified on KG1a cells, a human leukemia line that phenotypically
resembles the native stem cell.22-24
In early studies, we investigated whether CD34 on hematopoietic cells
functions as an L-selectin ligand. By using the shear-based L-selectin-specific Stamper-Woodruff assay,25 we found
that the CD34 glycoform present on hematopoietic cells is not an
L-selectin ligand. However, our studies showed that an L-selectin
ligand is expressed on KG1a cells and on normal human bone marrow
CD34+ hematopoietic progenitor cells.2,26 Like
endothelial L-selectin ligands, this hematopoietic cell L-selectin
ligand (HCLL) requires sialylation for activity. However, HCLL differs
in several fundamental ways from previously described endothelial
L-selectin ligands: It does not contain epitopes recognized by MECA 79, it is resistant to digestion with O-sialoglycoprotease (OSGP), a
peptidase that cleaves at sites of O-linked sialylated carbohydrate
modifications, and its activity is sulfation
independent.27
Subsequent to our description of HCLL activity on hematopoietic
progenitors, several groups reported that P-selectin glycoprotein ligand-1 (PSGL-1), a cell surface mucin-like glycoprotein that serves
as a P-selectin and E-selectin ligand,28,29 can also serve
as an L-selectin ligand.30-33 The binding determinants for both L- and P-selectins are localized to the N-terminal region of
mature PSGL-1 and are sensitive to cleavage by mocarhagin, a protease
that cleaves a 10 residue fragment from the N-terminus.32 PSGL-1 is expressed on neutrophils and on a variety of human myeloid cell lines (including HL60 and KG1a cells34-36), and is
also expressed on normal hematopoietic progenitors.36-38
However, contrary to L-selectin, engagement of PSGL-1 on progenitors
appears to inhibit hematopoiesis.6 This finding suggests
that the increased clonogenic activity associated with L-selectin
binding may be mediated by interactions with ligands other than PSGL-1.
In this report we show, by biochemical analysis of KG1a cells and
native circulating blasts from patients with acute leukemias, that HCLL
is a naturally expressed integral membrane glycoprotein L-selectin
ligand distinct from PSGL-1. The data also show that HCLL is uniquely
distinguished from all other L-selectin ligands in that L-selectin
binding determinant(s) are presented on N-linked complex carbohydrates.
Cells, antibodies, and enzymes
Immunofluorescence studies
Lymphocyte adherence assay The Stamper-Woodruff lymphocyte adherence assay was performed on glutaraldehyde-fixed cytocentrifuged (cytospin) preparations of cells as previously described,26 or on glutaraldehyde-fixed slides containing cell membrane protein preparations (see below). For all adherence assays, lymphocyte suspensions (107 per milliliter rat thoracic duct lymphocytes or human peripheral blood lymphocytes isolated by density centrifugation of citrated blood) in RPMI 1640 medium were overlaid onto glass slides containing cytospin preparations of cells, containing membrane protein preparations, or containing glutaraldehyde-fixed 8-µm-thick frozen sections of murine lymph node (which served as control to assess L-selectin-mediated lymphocyte binding to HEV). Slides were placed on a rotating platform for incubation under shear (80 rpm) at 4°C for 30 minutes. Slides were then rinsed in PBS to remove nonadherent lymphocytes, fixed in 3% glutaraldehyde, and stained with methyl green-thionin. Slides were examined for lymphocyte adherence to cells or to spotted membrane protein material by light microscopy. As previously described,26 L-selectin-specific lymphocyte adherence was verified in every assay by performing parallel incubations with phorbol myristate acetate (PMA)-treated lymphocytes (PMA induces shedding of L-selectin), by preincubation of lymphocytes with blocking anti-L-selectin moAb (either HRL-1 for rat or LAM1-3 for human lymphocytes, or with respective control isotype moAb), and by performing assays in the presence of 10 mmol/L EDTA.For cytospin preparations, L-selectin ligand activity was measured by counting the number of lymphocytes adherent to a confluent area of cytocentrifuged cells, using an ocular grid under 100 × magnification. In experiments in which cells were treated with enzymes, metabolic agents or antibodies, untreated (control) and treated cells were assayed in parallel; ligand activity was measured by counting respective adherent lymphocytes on a minimum of 3 separate grid fields of cytospins, 3 slides per experiment, 3 separate experiments. The mean lymphocyte binding for each treatment and control slide was quantified, and data were expressed as the percentage of lymphocyte binding of treated compared with untreated cells, as previously described.26,27 To assess blocking activity of anti-PSGL-1 antibodies, KG1a cytospins were preincubated in RPMI 1640 containing anti-PSGL-1 antibodies or isotype-matched antibody (controls) at concentrations as high as 50 µg/mL for 30 minutes at 4°C; slides were then rinsed and cell suspensions containing the respective antibodies at concentrations equivalent to those used in the preincubation were overlaid onto the slides. For experiments using cytospin mixtures of HL60 and KG1a cells, immunohistochemistry for CD34 antigen was performed as per manufacturer's (Dako, Carpinteria, CA) recommendations, after the adherence assay to identify KG1a cells (alkaline phosphatase, New Fuchsin chromagen; stained cells are pink). For Stamper-Woodruff adherence assays on preparations of cell membrane proteins, 1 µg membrane protein (prepared as described below) was spotted onto glass slides, allowed to dry at room temperature, and then fixed in 3% glutaraldehyde. Adherence assays were performed on these slides exactly as described for cytospin preparations of cells. After enzyme treatments of membrane protein, lymphocytes adhering to enzyme-treated and buffer-treated preparations were quantified as described above, with data expressed as a percentage of control lymphocyte adherence (enzyme-treated samples compared with corresponding buffer-treated membrane proteins). Enzyme digestions Cell suspensions (20 × 106 cells/mL RPMI) were treated with proteases or with buffer alone (control) before cytocentrifugation. Protease concentrations for digestions were as follows: 100 U/mL chymotrypsin; 0.1% bromelain; 50 mg/mL human neutrophil elastase or porcine pancreas elastase; O-sialoglycoprotease at 60 µg /mL; mocarhagin at 10 µg/mL. All digestions were 1 hour at 37°C in RPMI 1640 medium, except for mocarhagin digestion for which cells were suspended in 0.15 mol/L NaCl, 2 mmol/L CaCl2, 1 mg/mL BSA, 0.01 mol/L Tris, pH 7.4, for 20 minutes at 37°C. To verify the efficiency of O-sialoglycoprotease and of mocarhagin digestions, flow cytometry was performed to measure QBEND10 (an OSGP-sensitive epitope of CD34) and the PSL-275 epitope of PSGL-1, respectively. After digestions, cells were washed in RPMI 1640 medium, then cytocentrifuged onto slides for adherence assays. For digestion with Newcastle virus neuraminidase, glutaraldehyde-fixed cytospins of KG1a cells were rinsed twice with enzyme buffer (50 mmol/L NaAcetate, 154 mol/L NaCl, 9 mmol/L CaCl2, pH 5.5), and incubated at 37°C for 1 hour with 50 µL buffer (control) or 10 mU/mL neuraminidase in buffer; the slides were then washed in RPMI 1640/1% FBS, and the lymphocyte adherence assay was performed on the cytospins.For Analysis of ligand reexpression after neuraminidase or bromelain treatment of KG1a cells KG1a (20 × 106 cells/mL) were treated with 0.1 U/mL neuraminidase (V cholerae neuraminidase) in RPMI 1640 without bicarbonate (pH 7.4) for 1 hour at 37°C; for controls, an equivalent volume of enzyme buffer (one-tenth volume of 50 mmol/L sodium acetate, 154 mmol/L NaCl, 9 mmol/L CaCl2, pH 5.5) was added to KG1a in RPMI 1640 without bicarbonate (pH 7.4) under identical conditions (final pH 6.8). Bromelain digestion was performed as described above. After neuraminidase or bromelain digestion, cells were washed 3 times in RPMI 1640 without bicarbonate and an aliquot, designated as t = 0, was tested in the adherence assay to verify complete loss of ligand activity. The remaining cells were cultured in RPMI 1640/10% FBS and an aliquot of these cells was removed at serial time points over 24 hours for analysis of the reappearance of ligand activity in the adherence assay.Effects of metabolic inhibition of N-linked glycosylation or protein synthesis Tunicamycin (15 µg/mL) or diluent control (DMSO, final concentration 0.3%) was added to cell cultures (107 cells/mL in RPMI 1640 with 10% FBS) after either V cholera neuraminidase treatment (0.1 U/mL) or respective enzyme buffer treatment of the KG1a cells for 1 hour as described above. For metabolic studies utilizing either swainsonine or deoxymannojirimycin, cells were treated with neuraminidase and then washed and suspended in RPMI 1640/10% FBS containing either 0.4 mg/mL deoxymannojirimycin or 40 µg/mL swainsonine. Cells were incubated with metabolic inhibitors of glycosylation for 24 hours, then washed and cytocentrifuged onto glass slides for analysis of L-selectin-dependent lymphocyte adherence.For inhibition of protein synthesis, cycloheximide (Sigma, endotoxin-cleared27) was added to cultures of neuraminidase-digested, bromelain-digested, or buffer-treated KG1a (107 cells/mL in RPMI 1640/10% FBS) at 1.25 µg/mL final concentration. In each case, cells were cultured for 20 hours and the L-selectin ligand activity was measured by adherence assay at the end of the culture period. For all studies utilizing metabolic inhibitors, parallel cultures were established in the presence of 35S-methionine/cysteine, and protein synthesis was measured by scintillation counting of trichloroacetic acid (TCA)-precipitable protein as previously described.27 Salt and pH treatments of KG1a cells KG1a cells (50 × 106 cells) were incubated for 5 minutes at 37°C with vigorous agitation in 2 mL high salt solution (to 1 mol/L NaCl) under a variety of pH conditions: 0.1 mol/L Tris, pH 9; 0.1 mol/L sodium phosphate, pH 7; 0.1 mol/L sodium acetate, pH 5; and 0.1 mol/L acetic acid, pH 3. After these treatments, cells were centrifuged and supernatants collected. Cells were then washed in RPMI 1640 × 2, and cells and supernatants were assessed for ligand activity. Supernatants were spotted onto glass slides and air-dried, then glutaraldehyde fixed for Stamper-Woodruff assays. L-selectin ligand activity of these cells and supernatants was compared with cells similarly treated with agitation in RPMI 1640 medium alone.Isolation of KG1a membranes and organic solvent extraction of membranes KG1a membranes were isolated by nitrogen cavitation, followed by differential centrifugation to isolate membrane fractions.43 KG1a were suspended (4 × 108 cells/mL) in PI buffer (150 mmol/L NaCl, 50 mmol/L Tris-HCl pH 7.4, 1 mmol/L EDTA, 0.02% sodium azide, containing protease inhibitors [20 µg/mL PMSF, 0.5 µg/mL aprotinin, 0.5 µg/mL pepstatin A, 0.5 µg/mL leupeptin, 20 µg/mL trypsin inhibitor]) and subjected to nitrogen cavitation (400 psi). Ruptured cells were then centrifuged (3600g) to pellet nuclear and mitochondrial debris; the supernatant was saved, and the pellet was washed with PI buffer and recentrifuged. The 2 supernatants were then pooled and centrifuged (22 000g) to pellet membrane material that was then suspended in PI buffer.For lipid extractions, membrane preparations (0.2 mg/mL protein) were mixed (1:5) with organic solvents: water-saturated butanol or chloroform: methanol (2:1) for 3 minutes. Appropriate solvent to PBS mixtures (1:1) were then added at 10% of the above final volume and phases were separated by centrifugation. Aqueous and organic phases were evaporated, and resulting material was resuspended in original volume of PBS and spotted on glass slides, air-dried, then glutaraldehyde fixed for analysis in the Stamper-Woodruff assay.
PSGL-1 is not the principal L-selectin ligand on KG1a cells With the Stamper-Woodruff assay, lymphocyte adherence to cytospin preparations of cells or to membrane material spotted on glass slides was mediated only by L-selectin, as determined by complete elimination of lymphocyte adherence after PMA-treatment of lymphocytes, preincubation of lymphocytes with anti-L-selectin moAb, and by performing the assay in the presence of EDTA. Incubation of KG1a cytospin monolayers with anti-PSGL-1 monoclonal antibodies singly and in combination, including PL-1, 4F9, 4D8, and 2G3 (each of which block L- and P-selectin binding to PSGL-1), did not inhibit lymphocyte attachment in the adherence assay (Table 1). These incubations were performed both before and after glutaraldehyde fixation of KG1a onto glass slides, with antibody concentrations as high as 100 µg/mL, both singly and in combination. Moreover, incubation of KG1a with undiluted anti-PSGL-1 rabbit antisera Rb3443 did not interfere with L-selectin ligand activity in the adherence assay. In each case where antibodies were used, KG1a cells were stained with the respective antibody and isotype (or preimmune sera) control and analyzed by flow cytometry to confirm attachment to PSGL-1. HCLL activity was also unaffected by preincubation of KG1a with P-selectin-Ig chimera (Table 1).
Mocarhagin digestion abrogates both P-selectin and L-selectin binding
activity of PSGL-1.32 KG1a cells incubated with this protease were analyzed by flow cytometry for P-selectin binding utilizing P-selectin-Ig chimera. As shown in Figure
1, mocarhagin digestion completely
eliminated P-selectin binding to PSGL-1. Staining of KG1a cells with
N-terminal-specific moAb PSL-275 was similarly eliminated after
mocarhagin treatment, confirming the high efficiency of digestion of
the N-terminal region of PSGL-1. However, treatment of KG1a with
mocarhagin or enzyme buffer (control) did not affect
L-selectin-specific lymphocyte adherence in the Stamper-Woodruff assay
(Table 2). OSGP digestion of KG1a also eliminated P-selectin-Ig binding to KG1a cells (data not shown), without affecting HCLL activity (Table 2).
The hematopoietic cell line HL60 has been utilized extensively for
studies of PSGL-1 structure and function,28,29,34,37,40,44 and PSGL-1 on HL60 has been reported to be an L-selectin
ligand.30,31 As measured by binding of P-selectin-Ig
chimera, KG1a express functional levels of PSGL-1 comparable to HL60
cells (Figure 2A). However, in
Stamper-Woodruff assays of cytospin mixtures of KG1a and HL60 cells,
lymphocytes bind only to KG1a cells (pink staining cells, Figure 2B).
The selectivity and specificity of binding to KG1a in mixing studies
indicate that the absence of lymphocyte adherence to HL60 cells under
Stamper-Woodruff assay conditions is not due to an indirect biologic
effect of HL60 on lymphocytes rendering them incapable of attaching to
L-selectin ligands (such as activation-induced shedding of
L-selection45,46), as any such effect would concomitantly
prevent binding to KG1a in these cytospin mixtures.
To further examine the role of PSGL-1 in the L-selectin ligand activity
of KG1a cells, we separated KG1a cells into subpopulations with high-
and low-level expression of PSGL-1 by fluorescence-activated cell
sorting utilizing a cocktail of anti-PSGL-1 antibodies. Cytospin preparations of the separated populations were made and cells were then
analyzed for L-selectin ligand activity in the Stamper-Woodruff assay.
The adherence of lymphocytes was identical in the 2 populations (compared with presorted KG1a cells, mean [SEM] percentage binding was 100.6 [9.5] and 98.6 [11.1]) in the "low" and "high"
PSGL-1 groups, respectively), despite high-efficiency separation of
PSGL-1 expressing cells as verified by repeat staining using
anti-PSGL-1 antisera (Figure 3).
Hematopoietic cell L-selectin ligand is an integral membrane protein As shown in Table 2, treatment of KG1a cells with bromelain, chymotrypsin, and pronase completely abrogates L-selectin ligand activity, whereas digestion with pancreas and neutrophil elastase partially affects activity and digestion with mocarhagin, and O-sialoglycoprotease has no effect on ligand activity. Ligand activity is also resistant to digestion with PI-PLC (Table 2). Similar to previous data from our laboratory after neuraminidase treatment of KG1a,27 cycloheximide treatment of cells for as long as 20 hours after protease (bromelain) digestion completely prevents ligand reexpression without significantly affecting cell numbers or viability (trypan blue exclusion more than 95%) (Table 3).
To determine whether HCLL is an integral membrane structure, KG1a cells were treated with high salt conditions (to 1 mol/L NaCl) over a range of pH levels (pH 3-9), and supernatant (elution) and residual membrane fractions were tested in the Stamper-Woodruff assay. HCLL activity was detected only on membranes after all treatments (data not shown). To examine whether membrane lipid contributed to HCLL activity, organic solvent extractions of cells were performed, and respective organic and aqueous phases were then tested in the Stamper-Woodruff assay. In each case, ligand activity partitioned in the aqueous phase, and there was no activity within the lipid (solvent) compartment (data not shown). Hematopoietic cell L-selectin ligand L-selectin binding determinant(s) are sialylated, fucosylated structures displayed on complex N-linked glycans We previously showed that V cholera neuraminidase treatment completely abrogates HCLL activity on KG1a.24 This enzyme has broad specificity for cleavage of terminal sialic acids in either 2-3, 2-6, or 2-8 linkage to relevant
oligosaccharides. To further characterize the sialic acid linkage, we
used the Newcastle disease virus neuraminidase that cleaves terminal
sialic acids in 2-3 and 2-8 linkages, but not in 2-6
linkage.47,48 As with results of V cholera
neuraminidase digestions, treatment of KG1a cells with Newcastle
neuraminidase before the Stamper-Woodruff assay abrogated HCLL binding
activity (mean binding of 9.8% [SEM of 2.2%] compared with
respective buffer treatment alone, P < .001 by
paired t test). These data, specifically, indicate that
L-selectin binding determinant(s) on HCLL consist of oligosaccharides
principally bearing 2-3-and/or 2-8-linked sialic acids. To
examine whether fucosylation is required for ligand activity, we
digested denatured KG1a membrane preparations with -L-fucosidase,
which cleaves terminal fucose residues in 1,2-, 1,3-, and
1,4-linkages. Treatment with this enzyme markedly diminished HCLL
binding activity (mean binding of 11.5% [SEM of 2.9%] compared with
respective buffer treatment alone, P < .001 by
paired t test). Collectively, the results of sialidase and
fucosidase digestions indicate that the relevant binding determinant of
HCLL is a sialylated, fucosylated glycoconjugate.
Inhibition of protein synthesis with cycloheximide after either
neuraminidase27 or protease treatment (Table 3) prevents ligand reexpression. These data indicate that ligand reexpression after
such treatments results from de novo glycoprotein synthesis and
processing; thus, incubation of the cells with metabolic inhibitors of
glycosylation during the period of ligand reexpression would result in
replacement of original membrane ligand glycoprotein(s) with ligand
molecules affected by the relevant metabolic treatments. Accordingly,
to investigate the effect of modifications in N-linked oligosaccharide
processing on the activity of HCLL, we treated KG1a cells with V
cholera neuraminidase, and cultured these treated cells for 24 hours in the presence of glycosylation inhibitors, tunicamycin,
swainsonine, and deoxymannojirimycin (Figure
4A shows schema depicting the effects of
these inhibitors on the different stages of carbohydrate processing).
Before culturing the cells, the cleavage of sensitive sialic acid
epitopes was confirmed in every case by testing for loss of
binding activity in the Stamper-Woodruff assay and by measuring the
expression of the sialic acid-dependent L60 epitope of CD43 by flow
cytometry.27 For each inhibitor, effects on glycosylation
of membrane proteins were verified by analysis of protein band shifts
by SDS-PAGE of membrane lysates (data not shown); however, treatment of
cells with the glycosylation inhibitors did not affect cell viability
(trypan blue exclusion more than 98% for each inhibitor). As shown in
Table 4, treatment with glycosylation
inhibitors without prior neuraminidase digestion did not affect
L-selectin ligand activity of KG1a cells, suggesting that the membrane
turnover of fully processed HCLL is relatively slow and there is no
direct toxic effect of the inhibitors on the activity of HCLL already
expressed on the membrane. However, after neuraminidase digestion,
tunicamycin treatment completely prevented HCLL reexpression and both
swainsonine and deoxymannojirimycin markedly diminished expression of
HCLL activity. Return of the L60 epitope of CD43 was not inhibited by
treatments with either tunicamycin, swainsonine, or deoxymannojirimycin
(data not shown), indicating that these agents did not affect
sialylation directly and, in particular, did not affect synthesis of
O-linked sialylated structures. Moreover, similar to our findings
in previous studies,27 these metabolic agents had no
effect on de novo protein synthesis as TCA-precipitable
35S-methionine/cysteine radiolabeled protein counts were
similar to that of cells not treated with the inhibitors (data not
shown).
To further analyze the structural biology of the critical
glycosylations conferring ligand activity, Stamper-Woodruff assays were
performed on N-glycosidase and buffer (control) treated membrane preparations of KG1a cells. Interestingly, HCLL binding activity was
maintained after SDS solubilization and 2-mercaptoethanol treatment of
membrane proteins, indicating that the protein scaffold can be
denatured significantly without disturbing ligand activity. Figure 4B
displays the relevant specificity for each endo-N-glycosidase. As shown
in Table 5, N-glycosidase F digestion
completely abrogates HCLL activity, whereas endoglycosidase F2
digestion moderately affects activity and endoglycosidase H digestion
has no effect.
Hematopoietic cell L-selectin ligand is present on blasts from native acute leukemias Peripheral blood mononuclear cells (PBMCs) were isolated from blood of 9 patients with AML or ALL, in which blasts represented more than 80% of differential counts (by morphology and flow cytometry, blasts comprised more than 95% of isolated PBMCs). These specimens represent all samples available to date. CD34 and PSGL-1 levels were measured by flow cytometry, and OSGP- and mocarhagin-treated blasts were evaluated for HCLL activity by Stamper-Woodruff assay. All surveyed blasts showed OSGP- and mocarhagin-resistant HCLL activity at levels comparable to KG1a cells (Table 6). Blasts from a biphenotypic leukemia (Figure 5) and from an M2 were deficient in PSGL-1, and blasts from 2 patients (one M4 and one M5) lacked CD34, yet HCLL activity was high in all the blasts. As with KG1a cells, ligand activity on all blasts was sensitive to neuraminidase, bromelain, and chymotrypsin digestion, and N-glycosidase F digestion of membrane fractions prepared from 3 specimens (M2, M4, and M5) abrogated binding activity (binding less than 10% of untreated control). Of note, morphologically normal PBMCs (and granulocytes) from patients lacked HCLL activity.
Previous studies from our laboratory have identified an L-selectin ligand expressed on the human hematopoietic progenitor cell line KG1a and on normal human CD34+ hematopoietic progenitor cells.2,26 This ligand, designated HCLL, is distinguished from its endothelial counterparts by: (1) sulfation-independent binding activity; (2) resistance to inactivation by OSGP digestion; and (3) absence of MECA79 antigen.26,27 This study was undertaken to characterize the structural biology of HCLL. The data presented here indicate that HCLL is an integral membrane glycoprotein that is biochemically distinct from PSGL-1 and is unique among naturally expressed L-selectin ligands in that the L-selectin binding determinant(s) are presented on N-linked complex glycans. The earliest hematopoietic progenitor cells express PSGL-1, which is a ligand for all 3 selectins.49,50 The L-selectin binding determinant of PSGL-1 overlaps that of P-selectin in an N-terminal region, which is sensitive to OSGP and mocarhagin digestion.31-33,51 P-selectin and L-selectin binding to PSGL-1 is dependent on sulfation of tyrosines within this region,52,53 whereas critical sulfation occurs on carbohydrates on endothelial L-selectin ligands.18,54-56 KG1a express abundant levels of PSGL-1 and our previous studies did not directly address the relationship of HCLL to PSGL-1. Although the sulfation-independence and OSGP-resistance of HCLL contrasts with the L-selectin binding activity of PSGL-1, there is precedent for structural modifications in PSGL-1 conferring selective selectin binding: skin-homing T cells express PSGL-1 specifically decorated with the CLA epitope (a posttranslational carbohydrate modification recognized by the moAb HECA-452), which confers E-selectin binding.57 We therefore sought more direct evidence to establish whether HCLL activity was attributable to PSGL-1. The data reported here clearly demonstrate that the L-selectin binding activity of HCLL is independent of PSGL-1: (1) Mocarhagin and OSGP digestion were each completely effective in cleaving the L-selectin/P-selectin binding domain of the PSGL-1 molecule, but had no effect on HCLL activity; (2) experiments utilizing mixtures of KG1a cells and HL60 cells (which express equivalent levels of PSGL-1) reveal that only KG1a cells support L-selectin-dependent lymphocyte attachment in the Stamper-Woodruff assay; (3) antibody blocking studies utilizing both monoclonal and polyclonal reagents directed against L/P-selectin binding epitopes of PSGL-1 did not affect L-selectin-mediated lymphocyte binding of KG1a; (4) no difference in L-selectin-mediated lymphocyte adherence was observed in KG1a cells sorted for high and low levels of PSGL-1 expression; and (5) blasts from patients with acute leukemias deficient in PSGL-1 displayed high HCLL activity. Although apparently in contrast to results of previous studies,30-33 our finding that HCLL binding activity is not attributable to PSGL-1 does not negate a role for PSGL-1 as an L-selectin ligand. Rather, these data indicate that the biophysical requirements for PSGL-1-specific L-selectin binding are not met under the operative conditions of the conventional Stamper-Woodruff assay. Threshold biophysical shear forces are necessary to both promote and maintain L-selectin adherence to its ligands.58 Many studies directed at identifying L-selectin ligands have utilized static assay conditions and have relied on probes such as L-selectin-Ig chimeras or isolated molecules presented in nonphysiologic conditions (such as in high concentrations in solution or as displayed on artificial substrates). Compared with these approaches, the Stamper-Woodruff assay offers an important advantage in that it measures functional adhesive interactions under shear conditions of native L-selectin, as expressed naturally on the membrane of a physiologic cell type (the lymphocyte), with its relevant ligand(s) expressed in their native state in natural lipid bilayers of cell membranes. A variety of selectin ligands have been described, including membrane glycoproteins and glycolipids, secreted glycoproteins, and even extracellular matrix elements.15,49 The results of glycosidase and protease digestions and of metabolic inhibition of both protein and glycoconjugate synthesis indicate that the relevant HCLL carbohydrate binding determinants are sialofucosylated glycans expressed on a protein core. The partitioning of the activity in the aqueous phase of organic solvent extractions argues strongly against a significant component of glycolipid to HCLL activity. Moreover, resistance to PI-PLC digestion and to elution after treatment with high salt buffers over various pH levels indicates that HCLL is an integral membrane glycoprotein. All other glycoprotein L-selectin ligands (including PSGL-1) are sialomucins sensitive to OSGP, which express relevant carbohydrate L-selectin binding determinant(s) on O-linked glycans.31-33,51,59,60 The results presented here provide 2 independent lines of evidence, obtained from separate but complementary experimental approaches (N-glycosidase digestions and treatment of cells with metabolic inhibitors of glycosylation), which show that critical L-selectin binding determinants on HCLL are presented on N-linked glycans. The diminished reexpression of ligand activity in the presence of glycosylation inhibitors after desialylation was not due to a general inhibition of sialylation because the L60 epitope of CD43 was reexpressed completely in the presence of these agents. Moreover, it was not secondary to inhibition of protein synthesis of the cells, as 35S-methionine/cysteine incorporation into nascent protein (assessed by measurement of TCA-precipitable radioactive protein) was not significantly changed in the presence of any of the N-linked glycosylation inhibitors. The relevant N-linked glycan modification of HCLL that contains the L-selectin binding determinant(s) is, at minimum, a biantennary complex (ie, modified at both Man-1,6 and Man-1,3 arms) structure (Figure 4A). N-glycosidase F hydrolyzes all types of N-glycan structures in mammalian glycoproteins,61 whereas the substrate specificity of endoglycosidase H is high mannose and hybrid structures61,62 and endoglycosidase F2 hydrolyzes only complex biantennary and high mannose structures62,63 (Figure 4B). The observation that endoglycosidase F2 and N-glycosidase F digestions significantly affect HCLL binding activity, whereas endoglycosidase H digestion has no effect on HCLL activity, excludes unmodified high mannose and hybrid structures from consideration and, in particular, indicates that biantennary complex and multiantennary complex structures display the relevant L-selectin binding determinant(s). Moreover, metabolic treatments with either swainsonine or deoxymannojirimycin inhibit recovery of HCLL binding activity after neuraminidase treatment of the cells, which is also consistent with a minimum requirement for a biantennary complex structure (Figure 4A). Specifically, the inhibition by swainsonine suggests that modification of the Man-1,6 arm (in addition to the Man-1,3 arm) is crucial for full expression of ligand activity (Figure 4A). Of note, HCLL activity withstands protein denaturation in 1% SDS and 1% 2-mercaptoethanol (as present in the glycosidase buffers), suggesting that the core protein functions predominantly as a scaffold for the relevant ligand-specific carbohydrate modifications and that these N-linked carbohydrates direct the conformational/structural specificity for binding activity. The results of this study offer important new insights into the
complexity and breadth of L-selectin ligands. The data presented here
provide first evidence of a naturally expressed L-selectin ligand with
N-glycan-dependent binding activity. We have previously described that
this novel L-selectin ligand is expressed among normal
CD34+ hematopoietic progenitor cells but is absent in
CD34 L-selectin/ligand interactions confer shear-resistance, a property
critical to initial seeding of progenitors within the hematopoietic microenvironment after stem cell transplantation. On bone marrow cells,
L-selectin expression is absent on stromal elements, but mature
leukocytes and the earliest hematopoietic progenitors are typically
L-selectin+, whereas intermediate stages of leukocyte
development and erythrocyte and megakaryocytic lineage cells are
L-selectin
We are grateful to Dr Xhizhuang Shu, Jack Y. Lee, Geoffrey E. Grove, and Bozena Antoniu for excellent technical assistance. We wish to thank Dr Richard M. Stone, Dr Jeffrey Kutok, Dr Daniel Deangelo, and Ms Ilene A. Galinsky for assistance in procuring leukemia specimens, and Drs Dale A. Cumming, Anthony L. Tarantino, Robert C. Fuhlbrigge, and Thomas S. Kupper for helpful discussions and for critical review of the manuscript. This report is dedicated to the memory of Ms Ann M. ("Annie") Ferguson.
Submitted January 7, 2000; accepted June 21, 2000.
Supported by National Institutes of Health grant HL60528 (R.S.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Robert Sackstein, Harvard Institutes of Medicine, 77 Ave Louis Pasteur, Rm 671, Boston, MA 02115; e-mail: rsackstein{at}rics.bwh.harvard.edu.
1.
Carlos TM, Harlan JM.
Leukocyte-endothelial adhesion molecules.
Blood.
1994;84:2068-2101 2. Sackstein R. Expression of an L-selectin ligand on hematopoietic progenitor cells. Acta Haematol. 1997;97:22-28[Medline] [Order article via Infotrieve].
3.
Mazo IB, Gutierrez-Ramos J-C, Frenette PS, Hynes RO, Wagner DD, von Andrian UH.
Hematopoietic progenitor cells rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1.
J Exp Med.
1998;188:465-474 4. Simmons P, Zannettino A, Gronthos S, Leavesley D. Potential adhesion mechanisms for localization of hematopoietic progenitors to bone marrow stroma. Leuk Lymphoma. 1994;12:353-363[Medline] [Order article via Infotrieve].
5.
Verfaille CM.
Adhesion receptors as regulators of the hematopoietic process.
Blood.
1998;92:2609-2612 6. Lévesque J-P, Zannettino ACW, Pudney M, et al. PSGL-1-mediated adhesion of human hematopoietic progenitors to P-selectin results in suppression of hematopoiesis. Immunity. 1999;11:369-378[Medline] [Order article via Infotrieve]. 7. Koenig JM, Baron S, Luo D, Benson NA, Deisseroth AB. L-selectin expression enhances clonogenesis of CD34+ cord blood progenitors. Pediatr Res. 1999;45:867-870[Medline] [Order article via Infotrieve].
8.
Dercksen MW, Gerritsen WR, Rodenhuis S, et al.
Expression of adhesion molecules on CD34+ L-selectin+ cells predicts a rapid platelet recovery after peripheral blood stem cell transplantation.
Blood.
1995;85:3313-3319 9. Watanabe T, Dave B, Heimann DG, Jackson JD, Kessinger A, Talmadge JE. Cell adhesion molecule expression on CD34+ cells in grafts and time to myeloid and platelet recovery after autologous stem cell transplantation. Exp Hematol. 1998;26:10-18[Medline] [Order article via Infotrieve]. 10. Schweitzer KM, Dräger AM, van der Valk P, et al. Constitutive expression of E-selectin and VCAM-1 on endothelial cells of the hematopoietic tissues. Am J Pathol. 1996;148:165-175[Abstract].
11.
Frenette PS, Subbarao S, Mazo IB, von Andrian UH, Wagner DD.
Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to the bone marrow.
Proc Natl Acad Sci U S A.
1998;95:14423-14428 12. Terstappen LWWM, Huang S, Bui N, Picker LJ. Induction of human hematopoietic stem cell outgrowth by L-selectin ligation [abstract]. Blood. 1993;82:109a.
13.
Gunji Y, Nakamura M, Hayakawa T, et al.
Expression and function of adhesion molecules on human hematopoietic stem cells: CD34+ LFA-1- cells are more primitive than CD34+ LFA-1+ cells.
Blood.
1992;80:429-436 14. Bertozzi CR. Cracking the carbohydrate code for selectin recognition. Chem Biol. 1995;2:703-708[Medline] [Order article via Infotrieve].
15.
Varki A.
Selectin ligands.
Proc Natl Acad Sci U S A.
1994;91:7390-7397
16.
Imai Y, Singer MS, Fennie C, Lasky LA, Rosen SD.
Identification of a carbohydrate-based endothelial ligand for a lymphocyte homing receptor.
J Cell Biol.
1991;113:1213-1221 17. Lasky LA, Singer MS, Dowbenko D, et al. An endothelial ligand for L-selectin is a novel mucin-like molecule. Cell. 1992;69:927-938[Medline] [Order article via Infotrieve].
18.
Hemmerich S, Butcher E, Rosen SD.
Sulfation-dependent recognition of high endothelial venules (HEV)-ligands by L-selectin and MECA 79, an adhesion-blocking monoclonal antibody.
J Exp Med.
1994;180:2219-2226
19.
Sassetti C, Tangemann K, Singer MS, Kershaw DB, Rosen SD.
Identification of podocalyxin-like protein as a high endothelial venule ligand for L-selectin: parallels to CD34.
J Exp Med.
1998;187:1965-1975
20.
Streeter PR, Rouse BTN, Butcher EC.
Immunohistologic and functional characterization of a vascular addressin involved in lymphocyte homing into peripheral lymph nodes.
J Cell Biol.
1988;107:1853-1862
21.
Baumhueter S, Singer MS, Henzel W, et al.
Binding of L-selectin to the vascular sialomucin CD34.
Science.
1993;262:436-438 22. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoiesis III: a hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol. 1984;133:157-165[Abstract].
23.
Koeffler HP, Billing R, Lusis AJ, Sparkes R, Golde DW.
An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KG-1).
Blood.
1980;56:265-273
24.
Francis K, Ramakrishna R, Holloway W, Pallson BO.
Two new pseudopod morphologies displayed by the human hematopoietic KG1a progenitor cell line and by primary human CD34+ cells.
Blood.
1998;92:3616-3623
25.
Stamper HB, Woodruff JJ.
Lymphocyte homing into lymph nodes: in vitro demonstration of the selective affinity of recirculating lymphocytes for high-endothelial venules.
J Exp Med.
1976;144:828-833
26.
Oxley SM, Sackstein R.
Detection of an L-selectin ligand on a hematopoietic progenitor cell line.
Blood.
1994;84:3299-3306
27.
Sackstein R, Fu L, Allen KL.
A hematopoietic cell L-selectin ligand exhibits sulfate-independent binding activity.
Blood.
1997;89:2773-2781 28. Sako D, Chang XJ, Barone KM, et al. Expression cloning of a functional glycoprotein ligand for P-selectin. Cell. 1993;75:1179-1186[Medline] [Order article via Infotrieve].
29.
Asa D, Raycroft L, Ma L, et al.
The P-selectin glycoprotein ligand functions as a common human leukocyte ligand for P- and E-selectins.
J Biol Chem.
1995;270:11662-11670 30. Walcheck B, Moore KL, McEver RP, Kishimoto TK. Neutrophil-neutrophil interactions under hydrodynamic shear stress involve L-selectin and PSGL-1. J Clin Invest. 1996;98:1081-1087[Medline] [Order article via Infotrieve].
31.
Guyer DA, Moore KL, Lynam EB, et al.
P-selectin glycoprotein ligand-1 (PSGL-1) is a ligand for L-selectin in neutrophil aggregation.
Blood.
1996;88:2415-2421
32.
Spertini O, Cordey A-S, Monai N, Giuffré LL, Schapira M.
P-selectin glycoprotein ligand 1 is a ligand for L-selectin on neutrophils, monocytes and CD34+ hematopoietic progenitor cells.
J Cell Biol.
1996;135:523-531 33. Tu L, Chen A, Delahunty MD, et al. L-selectin binds to P-selectin glycoprotein ligand-1 on leukocytes: interactions between the lectin, epidermal growth factor and consensus repeat domains of the selectins determine ligand binding specificity. J Immunol. 1996;157:3995-4004[Abstract].
34.
Zhou Q, Moore KL, Smith DF, Varki A, McEver RP, Cummings RD.
The selectin GMP-140 binds to sialylated, fucosylated lactosaminoglycans on both myeloid and nonmyeloid cells.
J Cell Biol.
1991;115:557-564 35. Tracey JB, Rinder HM. Characterization of the P-selectin ligand on human hematopoietic progenitors. Exp Hematol. 1996;24:1494-1500[Medline] [Order article via Infotrieve].
36.
Zannettino ACW, Berndt MC, Butcher C, Butcher EC, Vadas MA, Simmons PJ.
Primitive human hematopoietic progenitors adhere to P-selectin (CD62P).
Blood.
1995;85:3466-3477
37.
Laszik K, Jansen PJ, Cummings RD, Tedder TF, McEver RP, Moore KL.
P-selectin glycoprotein ligand-1 is broadly expressed in cells of myeloid, lymphoid and dendritic lineage and in some nonhematopoietic cells.
Blood.
1996;88:3010-3012
38.
Greenberg AW, Kerr W, Hammer DA.
Relationship between selectin-mediated rolling of hematopoietic stem and progenitor cells and progression in hematopoietic development.
Blood.
2000;95:478-486
39.
Moore KL, Patel KD, Bruehl RE, et al.
P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin.
J Cell Biol.
1995;128:661-671
40.
Vachino G, Chang X-J, Veldman GM, et al.
P-selectin glycoprotein ligand-1 is the major counter-receptor for P-selectin on stimulated T cells and is widely distributed in non-functional form on many lymphocytic cells.
J Biol Chem.
1995;270:21966-21974
41.
Kumar R, Camphausen RT, Sullivan FX, Cumming DA.
Core2
42.
De Luca M, Dunlop LC, Andrews RK, et al.
A novel cobra venom metalloprotease, mocarhagin, cleaves a 10-amino acid peptide from the mature N terminus of P-selectin glycoprotein ligand receptor, PSGL-1 and abolishes P-selectin binding.
J Biol Chem.
1995;270:26734-26737
43.
Lemonnier F, Mescher M, Sherman L, Burakoff S.
The induction of cytolytic T lymphocytes with purified plasma membranes.
J Immunol.
1978;120:1114-1120
44.
Moore KL, Stults NL, Diaz S, et al.
Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells.
J Cell Biol.
1992;118:445-456 45. Jung T, Dailey M. Rapid modulation of homing receptors (gp90MEL-14) induced by activators of protein kinase C. J Immunol. 1990;144:3130-3136[Abstract].
46.
Kishimoto TK, Jutila MA, Butcher EC.
Identification of a human peripheral lymph node homing receptor: a rapidly down-regulated adhesion molecule.
Proc Natl Acad Sci U S A.
1990;87:2244-2248 47. Drzeniek R. Substrate specificity of neuraminidases. Histochem. 1973;5:271-290[Medline] [Order article via Infotrieve].
48.
Paulson JC, Weinstein J, Dorland L, van Halbeek H, Vliegenthart JF.
Newcastle disease virus contains a linkage-specific glycoprotein sialidase: application to the localization of sialic acid residues in N-linked oligosaccharides of alpha 1-acid glycoprotein.
J Biol Chem.
1982;257:12734-12738
49.
Kansas GS.
Selectins and their ligands: current concepts and controversies.
Blood.
1996;88:3259-3287 50. Moore KL. Structure and function of P-selectin glycoprotein ligand-1. Leuk Lymphoma. 1998;29:1-15[Medline] [Order article via Infotrieve].
51.
Norgard KE, Moore KL, Diaz S, et al.
Characterization of a specific ligand for P-selectin on myeloid cells: a minor glycoprotein with sialylated O-linked oligosaccharides.
J Biol Chem.
1993;268:12764-12774 52. Sako D, Comes KM, Barones KM, Camphausen RT, Cummings RA, Shaw GD. A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding. Cell. 1995;83:323-331[Medline] [Order article via Infotrieve]. 53. Li F, Wilkins PP, Crawley S, Weinstein J, Cummings RD, McEver RP. Post-translational modifications of recombinant P-selectin glycoprotein ligand-1 required for binding to P- and E-selectin. J Biol Chem. 1996;27:3255-3264.
54.
Bistrup A, Bhakta S, Lee JK, et al.
Sulfotransferases of two specificities function in the reconstitution of high endothelial cell ligands for L-selectin.
J Cell Biol.
1999;145:899-910
55.
Tangemann K, Bistrup A, Hemmerich S, Rosen S.
Sulfation of a high endothelial venule-expressed ligand for L-selectin: effects on tethering and rolling of lymphocytes.
J Exp Med.
1999;190:935-941
56.
Snapp KR, Ding H, Atkins H, Warnke R, Luscinskas FW, Kansas GS.
A novel P-selectin glycoprotein ligand-1 monoclonal antibody recognizes an epitope within the tyrosine sulfate motif of human PSGL-1 and blocks recognition of both P- and L-selectin.
Blood.
1998;91:154-164 57. Fuhlbrigge RC, Kieffer D, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T-cells. Nature. 1997;389:978-981[Medline] [Order article via Infotrieve]. 58. Finger EB, Puri KD, Alon R, Lawrence MB, von Adrian UH, Springer TA. Adhesion through L-selectin requires a threshold hydrodynamic shear. Nature. 1996;379:266-269[Medline] [Order article via Infotrieve].
59.
Puri KD, Finger EB, Gaudernack G, Springer TA.
Sialomucin CD34 is the major L-selectin ligand in human tonsil high endothelial venules.
J Cell Biol.
1995;131:261-270 60. Sassetti C, Tangemann K, Singer MS, Kershaw DB, Rosen SD. Identification of podocalyxin-like protein as a high endothelial venule ligand for L-selectin: parallels to CD34. J Exp Med. 1998;187:1965-1975. 61. Maley F, Trimble RB, Tarentino AL, Plummer TH. Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. Anal Biochem. 1989;180:195-204[Medline] [Order article via Infotrieve].
62.
Trimble RB, Tarentino AL.
Identification of distinct endoglycosidase (Endo) activities in Flavobacterium meningosepticum: Endo F1, Endo F2, and Endo F3.
J Biol Chem.
1991;266:1646-1651
63.
Tarentino AL, Quinone G, Changchien L-M, Plummer TH.
Multiple endoglycosidase F activities expressed by Flavobacterium meningosepticum endoglycosidases F2 and F3.
J Biol Chem.
1993;268:9702-9708 64. Sackstein R, Fu L, Allen KL, Janssen WE, Elfenbein GJ. A novel L-selectin ligand is expressed on normal human hematopoietic cells [abstract]. Exp Hematol. 1996;24:1079.
65.
Maly P, Thall AD, Petryniak B, et al.
The 66. Frenette PS, Mayadas TN, Rayburn H, Hynes RO, Wagner DD. Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins. Cell. 1996;84:563574. 67. Arbones ML, Ord DC, Ley K, et al. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity. 1994;1:247-260[Medline] [Order article via Infotrieve].
68.
Terstappen LWWM, Huang S, Picker LJ.
Flow cytometric assessment of human T-cell differentiation in thymus and bone marrow.
Blood.
1992;79:666-677 69. Kansas GS, Dailey MO. Expression of adhesion structures during B cell development in man. J Immunol. 1989;142:3058-3062[Abstract]. 70. Dimitroff CJ, Watts J, Schor K, Grove J, Lee J, Sackstein R. Novel L-selectin ligand activity with unique biophysical characteristics on hematopoietic progenitor cells [abstract]. Blood. 1999;94:255a.
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. N. Thomas, R. L. Schnaar, and K. Konstantopoulos Podocalyxin-like protein is an E-/L-selectin ligand on colon carcinoma cells: comparative biochemical properties of selectin ligands in host and tumor cells Am J Physiol Cell Physiol, March 1, 2009; 296(3): C505 - C513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Resto, M. M. Burdick, N. M. Dagia, S. D. McCammon, S. M. Fennewald, and R. Sackstein L-selectin-mediated Lymphocyte-Cancer Cell Interactions under Low Fluid Shear Conditions J. Biol. Chem., June 6, 2008; 283(23): 15816 - 15824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Narasipura, J. C. Wojciechowski, N. Charles, J. L. Liesveld, and M. R. King P-Selectin Coated Microtube for Enrichment of CD34+ Hematopoietic Stem and Progenitor Cells from Human Bone Marrow Clin. Chem., January 1, 2008; 54(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Napier, Z. R. Healy, R. L. Schnaar, and K. Konstantopoulos Selectin Ligand Expression Regulates the Initial Vascular Interactions of Colon Carcinoma Cells: THE ROLES OF CD44V AND ALTERNATIVE SIALOFUCOSYLATED SELECTIN LIGANDS J. Biol. Chem., February 9, 2007; 282(6): 3433 - 3441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Siddiqui, J. Pawelek, T. Handerson, C.-Y. Lin, R. B. Dickson, D. L. Rimm, and R. L. Camp Coexpression of {beta}1,6-N-Acetylglucosaminyltransferase V Glycoprotein Substrates Defines Aggressive Breast Cancers with Poor Outcome Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2517 - 2523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. D. Hanley, M. M. Burdick, K. Konstantopoulos, and R. Sackstein CD44 on LS174T Colon Carcinoma Cells Possesses E-Selectin Ligand Activity Cancer Res., July 1, 2005; 65(13): 5812 - 5817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Handerson, R. Camp, M. Harigopal, D. Rimm, and J. Pawelek {beta}1,6-Branched Oligosaccharides Are Increased in Lymph Node Metastases and Predict Poor Outcome in Breast Carcinoma Clin. Cancer Res., April 15, 2005; 11(8): 2969 - 2973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-C. Chen, C.-C. Huang, C.-L. Chien, C.-J. Jeng, H.-T. Su, E. Chiang, M.-R. Liu, C. H. H. Wu, C.-N. Chang, and R.-H. Lin Cross-linking of P-selectin glycoprotein ligand-1 induces death of activated T cells Blood, November 15, 2004; 104(10): 3233 - 3242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Biancone, V. Cantaluppi, D. Duo, M. C. Deregibus, C. Torre, and G. Camussi Role of L-Selectin in the Vascular Homing of Peripheral Blood-Derived Endothelial Progenitor Cells J. Immunol., October 15, 2004; 173(8): 5268 - 5274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Dimitroff, R. J. Bernacki, and R. Sackstein Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: implications in modulating lymphocyte migration to skin Blood, January 15, 2003; 101(2): 602 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Dimitroff, J. Y. Lee, K. S. Schor, B. M. Sandmaier, and R. Sackstein Differential L-Selectin Binding Activities of Human Hematopoietic Cell L-Selectin Ligands, HCELL and PSGL-1 J. Biol. Chem., December 7, 2001; 276(50): 47623 - 47631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Dimitroff, J. Y. Lee, S. Rafii, R. C. Fuhlbrigge, and R. Sackstein CD44 Is a Major E-Selectin Ligand on Human Hematopoietic Progenitor Cells J. Cell Biol., June 11, 2001; 153(6): 1277 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Kollet, A. Spiegel, A. Peled, I. Petit, T. Byk, R. Hershkoviz, E. Guetta, G. Barkai, A. Nagler, and T. Lapidot Rapid and efficient homing of human CD34+CD38{-}/lowCXCR4+ stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2mnull mice Blood, May 15, 2001; 97(10): 3283 - 3291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Prosper and C. M. Verfaillie Regulation of hematopoiesis through adhesion receptors J. Leukoc. Biol., March 1, 2001; 69(3): 307 - 316. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. J. Dimitroff, J. Y. Lee, R. C. Fuhlbrigge, and R. Sackstein A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells PNAS, November 22, 2000; (2000) 250484797. [Abstract] [Full Text]
|
|
|
|
|
|
C. J. Dimitroff, J. Y. Lee, R. C. Fuhlbrigge, and R. Sackstein A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells PNAS, December 5, 2000; 97(25): 13841 - 13846. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
and their ligands
1,2
N-acetylglucosaminyltransferase; Man II, 
indicates
mannose (man); 
, glucose (Glc); 
, N-acetylglucosamine (GlcNAc);
, fucose; 
, potential sites of chain elongation; 
, potential
addition of 
/lin+ progenitors and in mature
granulocytes and lymphocytes.